AVROBIO Inc - ESG Rating & Company Profile powered by AI
Full Sustainability assessment of AVROBIO Inc can be reached by registering for free. This page contains a free ESG report covering AVROBIO Inc. The ESG score includes 17 UN Sustainable Development Goals including: 'Quality Education', 'Climate Action' and 'Life below Water'.
AVROBIO Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 4.0, social score of 3.2 and governance score of 6.4.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 852 | Vaccibody AS | 4.6 | High |
| 852 | argenx SE | 4.6 | High |
| 868 | AVROBIO Inc | 4.5 | High |
| 868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
| 868 | Boiron SA | 4.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does AVROBIO Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes AVROBIO Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes AVROBIO Inc report the average age of the workforce?
Sign up for free to unlockDoes AVROBIO Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes AVROBIO Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes AVROBIO Inc disclose cybersecurity risks?
Sign up for free to unlockDoes AVROBIO Inc offer flexible work?
Sign up for free to unlockDoes AVROBIO Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes AVROBIO Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes AVROBIO Inc conduct supply chain audits?
Sign up for free to unlockDoes AVROBIO Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes AVROBIO Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes AVROBIO Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes AVROBIO Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes AVROBIO Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes AVROBIO Inc disclose water use targets?
Sign up for free to unlockDoes AVROBIO Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid AVROBIO Inc have a product recall in the last two years?
Sign up for free to unlockDoes AVROBIO Inc disclose incidents of discrimination?
Sign up for free to unlockDoes AVROBIO Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas AVROBIO Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes AVROBIO Inc disclose parental leave metrics?
Sign up for free to unlockDoes AVROBIO Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes AVROBIO Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes AVROBIO Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes AVROBIO Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes AVROBIO Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes AVROBIO Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs AVROBIO Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes AVROBIO Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes AVROBIO Inc disclose its waste policy?
Sign up for free to unlockDoes AVROBIO Inc report according to TCFD requirements?
Sign up for free to unlockDoes AVROBIO Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes AVROBIO Inc disclose energy use targets?
Sign up for free to unlockDoes AVROBIO Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes AVROBIO Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for AVROBIO Inc
These potential risks are based on the size, segment and geographies of the company.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.